trial · primary record
Donanemab
Alzheimer Disease
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 550 |
| Primary completion | 2029-09 |
| Primary endpoint | Change from Baseline as Measured by Clinical Dementia Rating - Sum of Boxes (CDR-SB) |
| Registry ID | NCT07602582 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:58.964Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07602582
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.